Home / AUROPHARMA.NS : NSE

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does AUROPHARMA.NS make money? Does AUROPHARMA.NS have pricing power? What's the Earnings Whisper? Will AUROPHARMA.NS profit more as the business scales? What is AUROPHARMA.NS's management track record? Is AUROPHARMA.NS's current price justified?

Aurobindo Pharma Limited

₹1666.9 +$473.90 (+39.72%)

NSE · 16 Oct 2026 09:58 UTC

Previous Close

₹1677.9

Day Range

₹1655₹1681.7

Year Range

₹1080.1₹1740

Market Cap

959.1B

AVG Volume

1.04M

Trailing/Forward PE

26.05/18.28

PEG ratio

0.89

Dividend Yield

Next Earnings Date

2026-11-14

Primary Exchange

National Stock Exchange of India

Revenue (INR) · A

AUROPHARMA.NS Revenue (INR) by year
Period	Revenue (INR)
2026	336.53B
2025	317.24B
2024	290.02B
2023	248.55B
2022	234.55B
2021	247.75B
2020	230.99B
2019	194.94B
2018	164.63B
2017	148.93B

Net Income (INR) · A

AUROPHARMA.NS Net Income (INR) by year
Period	Net Income (INR)
2026	35.05B
2025	34.86B
2024	31.73B
2023	19.28B
2022	26.48B
2021	53.35B
2020	28.45B
2019	23.65B
2018	24.23B
2017	23.02B

Operating Income (INR) · A

AUROPHARMA.NS Operating Income (INR) by year
Period	Operating Income (INR)
2026	72.8B
2025	120.01B
2024	104.5B
2023	73.8B
2022	66.56B
2021	83.51B
2020	80.56B
2019	64.47B
2018	66.24B
2017	-300K

EBITDA · A

Cash Flows · A

EPS · A

Expenses · A

Cash & Debt · A

Debt ratios · A

Margins · A

Return on Capital · A

Shares Outstanding · A

Dividends (INR) · A

Employee Count

Book Value Per Share · A

Total Assets · A

PE Ratio

Free Cash Flow Yield

Price to Sales

EV/EBITDA

Price/Operating Cashflow

Price to Book

No video analysis for this stock yet. Request one from our team.

AI Analysis

Aurobindo Pharma Limited

Video analysis: AUROPHARMA.NS

News: AUROPHARMA.NS

Similar companies